Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells Myeloproliferative neoplasms (MPNs) are a group of clonal disorders that arise from the transformation of hematopoietic stem cells. In 2005, several groups reported a single acquired point mutation in the Janus kinase 2 (Jak2) gene in the majority of patients with Philadelphia chromosome (Ph)-negative MPN. 1 The mutation is believed to have a critical role in the pathogenesis of these disorders, 2, 3 and it has been suggested that most patients harbor mutations (some of which remain to be identified) that potentially serve as a molecular target for selective Jak2 inhibition. 4 Although small molecule Jak2 inhibitors are entering clinical trials, their ultimate efficacy is unclear. 5 In addition to the concern of insufficient inhibition of mutated Jak2 in vivo or the emergence of resistance through activation of complementary pathways, many MPNs contain other mutational events (for example, mutation in exon12 of Mpl, 6 or the KIT D618V mutation in patients with systemic mastocytosis 7 ), and thus are not sensitive to Jak inhibitors. Therefore, the development of inhibitors to common mediators of diverse signaling pathways in this disease is very desirable.
One convergence point of these pathways is the transcription factor STAT5. STAT5 regulates the expression of genes controlling key events such as cell cycle progression and survival. Thus, continuous STAT5 activation drives increased expression of these genes that directly contribute to leukemogenesis. Continued STAT5 activation appears to be necessary for tumor cell survival, 8 although normal cells are generally tolerant to the loss of STAT5 function. Consequently, STAT5 is an attractive target for cancer therapy. Increasing evidence indicates that STAT5 activation is required for Jak2 V617F-mediated transformation. 9 As STAT5 is a critical mediator of the effects of Jak2 V617F, the development of drugs that inhibit this transcription factor holds promise as a treatment for MPN. Furthermore, the dual inhibition of both STAT5 and Jak2 may yield better disease control.
We previously identified the neuroleptic drug pimozide as an inhibitor of STAT5 transcriptional function in a cell-based screen. 10 In the present study, we evaluated the effect of pimozide alone and in combination with a Jak2 inhibitor on the biology of myeloproliferative cell lines. We examined a model system, Ba/F3 cells that had been reconstituted with erythropoietin receptor and the mutant form of Jak2 (BAFEJ), as well as the HEL and SET2 human leukemia cell lines that endogenously express Jak2 V617F. Treatment of each cell line with pimozide led to a decrease in tyrosine phosphorylation of STAT5 (Figure 1a and data not shown). Reflecting the fact that the phosphorylation of STAT5 is mediated by activated Jak2, the Jak2 inhibitor Jak inhibitor 1 also led to decreased phosphorylation of STAT5. STAT3 phosphorylation was only minimally affected by pimozide (Figure 1a) . Thus, the principal effect of pimozide in these MPN cell lines is the inhibition of STAT5 phosphorylation.
Three lines of evidence suggest that pimozide is not functioning as a classic kinase inhibitor. First, pimozide does not inhibit Jak family kinases in an isolated in vitro kinase assays (Table 1) . Second, its pattern of inhibition of substrate phosphorylation catalyzed by extracts from Jak2 V617F-expressing cells using the PamChip tyrosine kinase microarray system (PamGene, Den Bosch, Netherlands) 11 is clearly distinct from that mediated by a Jak inhibitor (including no inhibition of the phopshorylation of the Jak2 peptide by pimozide; Figure 1b ). Pimozide did inhibit phosphorylation of a peptide derived from Jak1, though this likely occurred through an indirect mechanism. Finally, other signaling pathways downstream of Jak2, such as the phosphorylation of extracellular signal-regulated kinase mitogen-activated protein kinases (MAPK) are not inhibited by pimozide (as they are with Jak inhibitor 1) in BAFEJ and HEL cells, and actually show a small but reproducible increased activity ( Figure 1c ). This finding is similar to that seen in cells transformed with BCR/ABL, 10 and may reflect a loss of a negative regulator of MAPK signaling that is STAT5 dependent.
12 Although the exact mechanism by which pimozide inhibits STAT5 phosphorylation is being elucidated, it may involve direct effects on STAT5 or on a negative regulator of STAT5 activation rather than by targeting a kinase.
Consistent with the central role of STAT5 activation in driving expression of genes underlying the malignant nature of these cells, inhibition of STAT5 phosphorylation by pimozide also led to a decrease in expression of STAT5 target genes ( Figure 1d ). Significantly, these include two important pro-survival genes, Bcl-xl and Mcl1. Bcl-xl appears to be a key mediator in promoting Jak2-mediated survival in SET2 cells 13 as inhibition of Jak2 signaling blocked STAT5-mediated regulation of Bcl-xl mRNA level and reduced its protein expression. Mcl1 is also a critical survival factor in MPN cells. Specific STAT5-docking domains have a major role in inducing Mcl1 expression driven by a mutated FLT3 containing an internal tandem duplication (FLT3-ITD), a mutation found in about 20% of acute myelogenous leukemia patients, independent of JAK2 activation. 14 Given that pimozide inhibits STAT5 tyrosine phosphorylation and decreases STAT5 target genes expression, we next determined whether pimozide also affects the viability of cells with activating mutations of Jak2. Pimozide caused a dose-dependent decrease in viability of the three cell lines, with IC 50 (half maximal inhibitory concentration) values ranging from 4 mM for BAFEJ and SET2 to 10 mM for HEL cells (Figure 1e and data not shown). As expected, pimozide also inhibits survival of parental Ba/F3 cells, which are known to be dependent on STAT5.
To determine the mechanism by which pimozide decreases viable cell numbers, BAFEJ and HEL cells were treated with pimozide for 24 h, after which they were permeabilized and stained with propidium iodide followed by flow cytometric analysis. In both cell lines, pimozide led to a prominent decrease in cells in S phase with a concomitant increase in cells in the G0/G1 phase of the cell cycle (Supplementary Figure 1a) .
As this change did not appear sufficient to explain the decrease in viable cell number observed, we treated the cells with pimozide for 48 h, after which they were stained with annexin V-FITC and propidium iodide followed by flow cytometric analysis. Pimozide led to an approximate threefold increase in apoptotic cells in both the lines, indicating that this drug induces both a cell cycle arrest and apoptosis, consistent with its effect on both pro-survival genes (Bcl-xl and Mcl-1) and genes promoting cell cycle progression (Cyclin D1; Supplementary Figure 1b) .
Given that pimozide and Jak inhibitor 1 both decrease STAT5 phosphorylation through distinct mechanisms, and the central roles performed both by mutated Jak2 and STAT5 in MPNs, we hypothesized that dual inhibition of both Jak2 and STAT5 may lead to enhanced effects on myeloproliferative cells. When HEL cells were treated with pimozide or Jak inhibitor 1, each of the drugs alone led to a 50% reduction in tyrosine phosphorylation of STAT5. However, when cells were treated with the combination, there was near-complete loss of STAT5 phosphorylation (Figure 2a) . Reflecting this combinatorial effect on STAT5 phosphorylation, treatment of HEL cells with the combination of pimozide and Jak inhibitor 1 also led to a greater reduction in the level of the pro-survival protein Mcl1 (Figure 2b ). It also led to a greater reduction in viable cells over a range of combinations in HEL cells as well as with the BAFEJ and SET2 cell lines (Figure 2c and data not shown). Thus, this dual inhibition of the Jak --STAT pathway leads to enhanced cytotoxicity of myeloproliferative cells.
To determine the mechanism for this combinatorial effect between pimozide and a Jak2 inhibitor, we analyzed the induction of apoptosis as measured by staining with annexin V-FITC and propidium iodide followed by flow cytometric analysis. In HEL cell line, the percentage of apoptotic cells increased from 8.2% at baseline to 23.1% with pimozide alone, and to 35.6% with Jak inhibitor 1. The combination of both drugs led to an increase of the apoptotic cells to almost 70% (Figure 2d) . Similar results were found in the BAFEJ cell line as well, over a range of concentration of both drugs (data not shown). Thus pimozide, particularly in combination with the Jak2 inhibitor Jak inhibitor 1, leads to a potent induction of apoptosis. 
The effect of pimozide on the activity of selected tyrosine kinases was analyzed using the SelectScreen Kinase Profiling service. This enhanced cytotoxic effect on myeloproliferative cells of pimozide in conjunction with a Jak inhibitor likely reflects both a more complete inhibition of STAT5 function, as well as inhibition of independent pathways downstream of activated Jak2. By inhibiting distinct targets, combination treatments may allow a greater cytotoxic effect on the tumor cells, and may decrease the emergence of drug resistance. Also, by allowing the use of lower concentrations of each drug, this strategy may minimize side effects.
Pimozide is approved for the treatment of Tourette's syndrome, and has a well described safety profile in humans. However, it can cause cardiac or neurologic toxicity, and thus it has a limited therapeutic window. Pimozide is not known to cause hematologic toxicity, and has very little effect on the survival of peripheral blood mononuclear cells from healthy donors or colony formation of CD34 þ cells from healthy individuals. 10 To determine the minimum exposure necessary to decrease viability of MPN cells, we exposed cells to pimozide for varying times, washed out the drug and then assessed survival in a standard 72 h viability assay (Supplementary Figure 1c) . These experiments showed that even brief exposures to pimozide were sufficient to induce some loss in viability. This may reflect the fact that loss of expression of STAT5-dependent pro-survival genes, such as Bcl-xl and Mcl1, may trigger an irreversible cell death pathway as occurs with oncogene addiction.
Even if it is not possible to achieve adequate levels of pimozide in patients to be used as a STAT5 inhibitor, these findings have several implications. They establish the utility of a direct STAT5 inhibitor in MPNs; they provide a chemical scaffold that may be modified to develop more efficacious and less toxic STAT5 inhibitors; and they provide a probe to allow the identification of unique cellular targets for STAT5 inhibition.
In conclusion, pimozide inhibits STAT5 activation in MPN cells, decreases STAT5-dependent gene expression and induces apoptosis in these cells. Notably, these effects are enhanced when pimozide is combined with Jak2 inhibition. These data suggest that directly inhibiting STAT5, as well as simultaneously inhibiting both STAT5 and Jak2, may be effective strategies for the treatment of MPN. Acute myeloid leukemia (AML) still has a rather poor prognosis, which is mainly ascribed to relapse in the majority of patients despite achievement of complete remission (CR). To prevent relapse, minimal residual disease (MRD) remaining in CR has to be completely eradicated. The graft-versus-leukemia effect induced by allogeneic hematopoietic stem cell transplantation is the most powerful mechanism for eradication of MRD, thus strongly suggesting the therapeutic potential of immunotherapy.
The Wilms' tumor gene WT1 is highly expressed in various types of malignancies, and the WT1 protein is one of the most promising leukemia and tumor-associated antigens. 1 --6 Based on findings of pre-clinical studies, we performed a phase I clinical study of WT1 peptide immunotherapy for patients with AML, myelodysplastic syndromes, breast or lung cancer, and were able to confirm the safety and clinical efficacy of this therapy. 7 In this report, we describe the long-term outcome for AML patients enrolled in this study.
The major inclusion criteria for vaccination were that patients had HLA-A*2402 and that WT1 mRNA levels, which reflect the amount of MRD, 8, 9 were 41 Â 10 3 or 41 Â 10 2 copies/mg RNA in bone marrow (BM) or peripheral blood (PB), respectively. A natural WT1 peptide (amino acid 235 --243 CMTWNQMNL) or the modified WT1 peptide (CYTWNQMNL) 10 emulsified with Montanide ISA51 adjuvant (Freund Corporation, Tokyo, Japan) was i.d. injected, and the vaccination was performed three times at 2-week intervals. The terms of both clinical and molecular responses were clearly defined as respectively, a decrease in leukemic blast cells in BM and a decrease in WT1 mRNA levels in BM and/or PB. Molecular CR was defined as undetectable levels of WT1 mRNA in PB (o50 copies/mg RNA). Molecular relapse was defined as abnormal levels of WT1 mRNA (X50 copies/mg RNA in PB and/or X1000 copies/mg RNA in BM). Vaccination was extended for patients who showed clinical response or no progression within 2 weeks from the end of three WT1 vaccinations. As for immunological monitering, WT1 tetramer þ CD8 þ T cells and IFN-g þ WT1 tetramer þ CD8 þ T cells were analyzed. Of the eight AML patients with hematological CR (leukemic blast o5%) but with MRD who were WT1-vaccinated, five patients who showed a decrease in WT1 mRNA levels (molecular response) were repeatedly WT1-vaccinated, but two relapsed later. The remaining three patients received WT1 vaccine for X8 years and have survived in molecular CR for X8 years without significant adverse effects except for local erythema at the vaccine injection sites (Table 1 ).
CASE REPORTS Case 1
A 32-year-old male was diagnosed as AML (M4Eo) in January 1997 and achieved hematological CR by induction chemotherapy. After
